Agile therapeutics announces findings of first-year post-marketing pharmacovigilance in acog poster presentation

Princeton, n.j., may 05, 2022 (globe newswire) -- agile therapeutics, inc. (nasdaq: agrx), a women's healthcare company, today publicly released the findings of its first year of post-marketing pharmacovigilance safety surveillance for twirla ® (levonorgestrel and ethinyl estradiol) transdermal system (lng/ee tds).

AGRX Ratings Summary

AGRX Quant Ranking